113 related articles for article (PubMed ID: 37216488)
1. Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study.
Rabbani S; Mattsson F; Lagergren J; Xie S
Acta Oncol; 2023 May; 62(5):438-443. PubMed ID: 37216488
[TBL] [Abstract][Full Text] [Related]
2. Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site.
Rabbani S; Santoni G; Lagergren J; Xie SH
Br J Cancer; 2022 Sep; 127(5):892-897. PubMed ID: 35715630
[TBL] [Abstract][Full Text] [Related]
3. Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study.
Holmberg D; Kauppila JH; Asplund J; Leijonmarck W; Mattsson F; Lagergren J
Gastric Cancer; 2024 May; 27(3):590-597. PubMed ID: 38430275
[TBL] [Abstract][Full Text] [Related]
4. Prognosis after surgery for gastric adenocarcinoma in the Swedish Gastric Cancer Surgery Study (SWEGASS).
Asplund J; Gottlieb-Vedi E; Leijonmarck W; Mattsson F; Lagergren J
Acta Oncol; 2021 Apr; 60(4):513-520. PubMed ID: 33502275
[TBL] [Abstract][Full Text] [Related]
5. Diverging trends in recent population-based survival rates in oesophageal and gastric cancer.
Lagergren J; Mattsson F
PLoS One; 2012; 7(7):e41352. PubMed ID: 22815994
[TBL] [Abstract][Full Text] [Related]
6. Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden.
Sundelöf M; Lagergren J; Ye W
Eur J Cancer; 2008 Jul; 44(11):1566-71. PubMed ID: 18434132
[TBL] [Abstract][Full Text] [Related]
7. Recent incidence trends of oesophago-gastric cancer in Sweden.
Abdulkarim D; Mattsson F; Lagergren J
Acta Oncol; 2022 Dec; 61(12):1490-1498. PubMed ID: 36594265
[TBL] [Abstract][Full Text] [Related]
8. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
9. Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.
Zheng J; Xie SH; Santoni G; Lagergren J
Br J Cancer; 2019 Nov; 121(10):877-882. PubMed ID: 31591459
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study.
Kauppila JH; Mattsson F; Brusselaers N; Lagergren J
BMJ Open; 2018 May; 8(5):e021495. PubMed ID: 29748347
[TBL] [Abstract][Full Text] [Related]
11. Aspirin or statin use in relation to survival after surgery for esophageal cancer: a population-based cohort study.
Holmberg D; Gottlieb-Vedi E; Hedberg J; Lindblad M; Mattsson F; Lagergren J
BMC Cancer; 2023 Apr; 23(1):375. PubMed ID: 37098462
[TBL] [Abstract][Full Text] [Related]
12. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.
Kauppila JH; Wahlin K; Lagergren P; Lagergren J
Int J Cancer; 2019 Mar; 144(6):1284-1291. PubMed ID: 30168595
[TBL] [Abstract][Full Text] [Related]
14. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma.
Holmberg D; Kauppila JH; Mattsson F; Asplund J; Leijonmarck W; Xie SH; Lagergren J
Gastric Cancer; 2022 May; 25(3):652-658. PubMed ID: 35166957
[TBL] [Abstract][Full Text] [Related]
15. Weekday of gastrectomy and long-term survival in gastric adenocarcinoma.
Leijonmarck W; Asplund J; Markar SR; Mattsson F; Lagergren J
Eur J Surg Oncol; 2023 Jan; 49(1):83-88. PubMed ID: 35922280
[TBL] [Abstract][Full Text] [Related]
16. Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study.
Zheng J; Santoni G; Xie SH; Lagergren J
Br J Cancer; 2021 Jul; 125(2):277-283. PubMed ID: 33972744
[TBL] [Abstract][Full Text] [Related]
17. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
18. Marital status and survival after oesophageal cancer surgery: a population-based nationwide cohort study in Sweden.
Brusselaers N; Mattsson F; Johar A; Wikman A; Lagergren P; Lagergren J; Ljung R
BMJ Open; 2014 Jun; 4(6):e005418. PubMed ID: 24907248
[TBL] [Abstract][Full Text] [Related]
19. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer.
Shore R; Yu J; Ye W; Lagergren J; Rutegård M; Akre O; Stattin P; Lindblad M
Sci Rep; 2021 Jun; 11(1):13486. PubMed ID: 34188067
[TBL] [Abstract][Full Text] [Related]
20. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study.
Busby J; Karasneh R; Murchie P; McMenamin Ú; Gadalla SM; Camargo MC; Iversen L; Lee AJ; Spence AD; Cardwell CR
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):48-56. PubMed ID: 31713940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
